Last $226.31 USD
Change Today -1.41 / -0.62%
Volume 1.1M
As of 4:15 PM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

actavis plc (ACT) Snapshot

Open
$227.50
Previous Close
$227.72
Day High
$228.21
Day Low
$224.94
52 Week High
02/26/14 - $230.77
52 Week Low
08/28/13 - $130.06
Market Cap
59.8B
Average Volume 10 Days
1.8M
EPS TTM
$4.55
Shares Outstanding
264.3M
EX-Date
--
P/E TM
49.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for ACTAVIS PLC (ACT)

actavis plc (ACT) Related Businessweek News

View More BusinessWeek News

actavis plc (ACT) Details

Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. It operates in three segments: Actavis Pharma, Actavis Specialty Brands, and Anda Distribution. The Actavis Pharma segment provides generic, branded generic, and over-the-counter (OTC) pharmaceutical products. This segment sells generic prescription products primarily under the Watson Laboratories, Watson Pharma, and Actavis Pharma labels; and OTC generic products under private label. The Actavis Specialty Brands segment offers patent-protected products and trademarked off-patent products, which are marketed as branded pharmaceutical products to physicians, specifically urologists, obstetricians, dermatologists, gastroenterologists, and gynecologists. The Anda Distribution segment primarily distributes generic and selected brand pharmaceutical products, vaccines, injectables, and OTC medicines to independent pharmacies, and to alternate care providers comprising hospitals, nursing homes, and mail order pharmacies, as well as to pharmacy chains, physicians’ offices, and buying groups. The company also develops and out-licenses generic pharmaceutical products primarily in Europe through its third-party business; and provides products in women's health, urology, gastroenterology, and dermatology therapeutic categories. The company has a collaboration agreement with Amgen, Inc. for the development and commercialization of various oncology antibody biosimilar medicines; and a collaboration agreement with Hanmi Pharm. Co. Ltd. to develop Hyalrheuma, a hyaluronic acid injection for arthritis pain treatment. Actavis plc was founded in 1983 and is headquartered in Parsippany, New Jersey.

actavis plc (ACT) Top Compensated Officers

Executive Chairman
Total Annual Compensation: $2.6M
Chief Financial Officer of Global
Total Annual Compensation: $557.3K
Chief Operating Officer
Total Annual Compensation: $639.5K
Executive Vice President of Commercial - Nort...
Total Annual Compensation: $557.7K
Compensation as of Fiscal Year 2013.

actavis plc (ACT) Key Developments

Actavis Confirms Generic Neupro(R) Patent Challenge

Actavis plc confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Rotigotine Extended-release Transdermal Film, 1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr. Actavis' ANDA product is a generic version of UCB's Neupro(R), which is indicated for the treatment of signs and symptoms of idiopathic Parkinson's disease and moderate-to-severe primary Restless Legs Syndrome (RLS).

United States District Court for the District of New Jersey Rules in Favor of Depomed, Inc. Patent Litigation Lawsuit against Actavis Elizabeth and Actavis

On August 19, 2014, Judge Joel A. Pisano of the United States District Court for the District of New Jersey ruled in favor of Depomed Inc. in the Company's patent litigation lawsuit against Actavis Elizabeth LLC and Actavis Inc. related to an Abbreviated New Drug Application filed by Actavis seeking to market generic versions of the company's Gralise (gabapentin) product prior to the expiration of the Company's patents asserted in the litigation. Judge Pisano's ruling finds that Actavis infringes all seven of the company's patents asserted in the litigation and upholds the validity of the patents. The latest expiration of the infringed patents is February 2024.

Pfizer Eyes Actavis And AstraZeneca

Pfizer Inc. (NYSE:PFE) is looking at new targets for acquisitions, Bloomberg reports. Pfizer is making an attempt to acquire AstraZeneca PLC (LSE:AZN). It is also considering other alternatives including Actavis plc (NYSE:ACT). Under U.K. takeover rules Pfizer can make the first steps toward a renewed bid on August 26, 2014. While it weighs that approach, Pfizer also is looking at other possible targets, including Actavis plc (NYSE:ACT), said people familiar with the matter. Pfizer Chief Executive Officer Ian Read has said he’s also looking for a deal that will yield cost reductions and a way to lower Pfizer’s tax rate and access overseas cash. “We will continue to evaluate all opportunities, regardless of size, through the lens of value creation for our shareholders and enhancing the competitiveness of our business,” Joan Campion, a spokeswoman for New York-based Pfizer, said in an e-mail.AstraZeneca declined to comment on Pfizer’s interest, citing the U.K.takeover panel’s rules. David Belian, a spokesman for Actavis, didn’t immediately return a call and e-mail message seeking comment.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACT:US $226.31 USD -1.41

ACT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACT.
View Industry Companies
 

Industry Analysis

ACT

Industry Average

Valuation ACT Industry Range
No financial data is available for ACT.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTAVIS PLC, please visit www.actavis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.